Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12577225-B2

Patent

Publication Date

2026-03-17

Expiration Date


Abstract

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.

Core Innovation

The disclosure describes nuclear-transport-modulating compounds and pharmaceutical compositions comprising a compound of structural formula IV, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In the independent claim, R2 is selected from optionally substituted heteroaryl. The description identifies substituted 1,2,4-triazole acrylamides, including 3,5-bis(trifluoromethyl)phenyl-1,2,4-triazole analogs bearing heteroaryl substituents and cis/trans exocyclic double-bond isomers, as CRM1 (exportin-1/XPO1) inhibitors for treating disorders involving abnormal nuclear transport.

Reported evaluations include CRM1-mediated nuclear-export inhibition, a Rev-GFP screening result of approximately 40 nM for compound 124, antiproliferative activity in cancer cell lines, XPO1 cargo modulation, and glioblastoma spheroid inhibition. Animal studies describe reduced arthritis scores and inhibited tumor growth across proposed formulations and combination treatments. Because background sections are omitted from the supplied text, the problem being solved is not explicitly described in patent.

Claims Coverage

The provided claim information identifies one independent claim directed to a pharmaceutical composition, encompassing four inventive features.

Pharmaceutical composition comprising a formula IV compound

Claim 1 recites a pharmaceutical composition comprising a compound represented by structural formula IV, or a pharmaceutically acceptable salt thereof, wherein R2 is selected from optionally substituted heteroaryl, and a pharmaceutically acceptable carrier.

Optionally substituted heteroaryl groups

Dependent claims specify R2 as an optionally substituted five- or six-membered heteroaryl containing one, two, or three nitrogen, oxygen, or sulfur atoms, identifying pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, and oxadiazolyl groups, with one to three substituents selected from listed substituent classes.

Treatment of specified cancers and myelodysplastic syndrome

Dependent claims describe administering the pharmaceutical composition to treat multiple myeloma, diffuse large B-cell lymphoma, acute myeloid leukemia, follicular lymphoma, or myelodysplastic syndrome, and identify oral administration as a refinement for the cancer-treatment method.

Promotion of wound healing

Dependent claims describe use of the pharmaceutical composition in a method for promoting wound healing.

The claim coverage centers on the formula IV pharmaceutical composition with an optionally substituted heteroaryl R2 group, along with dependent limitations specifying heteroaryl structures and methods of medical treatment or wound healing.

Stated Advantages

The description reports synergistic effects for combination treatment with doxorubicin or bortezomib.

Documented Applications

Treatment of cancer, including multiple myeloma, diffuse large B-cell lymphoma, acute myeloid leukemia, follicular lymphoma, and glioblastoma spheroids, including via oral administration.

Treatment of myelodysplastic syndrome.

Promotion of wound healing.

Treatment of CRM1-associated disorders involving abnormal nuclear transport, including inflammatory conditions such as arthritis, viral infections, ophthalmic conditions, and neurologic or neurodegenerative disorders.

Combination treatments combining the pharmaceutical composition with other therapeutic agents, including doxorubicin or bortezomib.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.